A Phase II Study of Radium-223 in Combination With Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer

NCT02225704 Phase 2 COMPLETED

This study aims to determine the safety and tolerability of Radium-223 when administered in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.

Details

Lead sponsor	Cancer Trials Ireland
Phase	Phase 2
Status	COMPLETED
Enrolment	45
Start date	2015-06-03
Completion	2021-11-23

Conditions

• Prostate Cancer

Interventions

• Radium-223 and enzalutamide

Primary outcomes

• To determine safety — approximately 6 to 9 months
  To record the incidence of grade 3 or higher adverse events during the period of combination therapy; graded according to the NCI CTCAE version 4

Countries

Ireland